EP1240201A4 - Oxidized apolipoproteins and methods of use - Google Patents

Oxidized apolipoproteins and methods of use

Info

Publication number
EP1240201A4
EP1240201A4 EP00979269A EP00979269A EP1240201A4 EP 1240201 A4 EP1240201 A4 EP 1240201A4 EP 00979269 A EP00979269 A EP 00979269A EP 00979269 A EP00979269 A EP 00979269A EP 1240201 A4 EP1240201 A4 EP 1240201A4
Authority
EP
European Patent Office
Prior art keywords
methods
apolipoproteins
oxidized
oxidized apolipoproteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00979269A
Other languages
German (de)
French (fr)
Other versions
EP1240201A1 (en
Inventor
Roland Stocker
Xing Li Wang
David Wilcken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heart Research Institute Ltd
Original Assignee
Heart Research Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heart Research Institute Ltd filed Critical Heart Research Institute Ltd
Publication of EP1240201A1 publication Critical patent/EP1240201A1/en
Publication of EP1240201A4 publication Critical patent/EP1240201A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP00979269A 1999-11-26 2000-11-27 Oxidized apolipoproteins and methods of use Withdrawn EP1240201A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ429399 1999-11-26
AUPQ4293A AUPQ429399A0 (en) 1999-11-26 1999-11-26 Oxidized apolipoproteins and methods of use
PCT/AU2000/001463 WO2001038395A1 (en) 1999-11-26 2000-11-27 Oxidized apolipoproteins and methods of use

Publications (2)

Publication Number Publication Date
EP1240201A1 EP1240201A1 (en) 2002-09-18
EP1240201A4 true EP1240201A4 (en) 2004-03-17

Family

ID=3818435

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00979269A Withdrawn EP1240201A4 (en) 1999-11-26 2000-11-27 Oxidized apolipoproteins and methods of use

Country Status (6)

Country Link
EP (1) EP1240201A4 (en)
JP (1) JP2003514918A (en)
AU (1) AUPQ429399A0 (en)
CA (1) CA2392355A1 (en)
NZ (1) NZ519040A (en)
WO (1) WO2001038395A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10035352A1 (en) * 2000-07-20 2002-01-31 Zlb Bioplasma Ag Bern Procedure for the treatment of unstable angina pectoris
EP1425031B8 (en) 2001-08-20 2008-09-03 CSL Behring AG Hdl for the treatment of stroke and other ischemic conditions
US7052849B2 (en) * 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
EP1697746B1 (en) 2003-12-05 2012-02-22 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
AU2011235920B2 (en) * 2003-12-05 2013-05-16 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
EP1787116A4 (en) * 2004-07-19 2008-05-28 Univ Washington Methods for assessing the risk for development of cardiovascular disease
US7378396B2 (en) 2004-08-11 2008-05-27 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
CA2586936C (en) * 2004-11-09 2019-08-20 Hill's Pet Nutrition, Inc. Use of antioxidants for gene modulation
US7956035B2 (en) 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US10894098B2 (en) * 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
GB2500856A (en) * 2011-01-19 2013-10-02 Eduardo Motta Alves Peixoto Pharmaceutical composition for treating oxidative stress-induced pathology and use thereof
CN110082452B (en) * 2019-05-23 2022-04-05 南京生命能科技开发有限公司 Detection method of azobisisobutyramidine dihydrochloride

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0722086A4 (en) * 1993-09-29 2000-10-25 Yamasa Corp Method of assaying oxidized lipoprotein and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PANZENBOECK UTE ET AL: "Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 47, 21 November 1997 (1997-11-21), pages 29711 - 29720, XP002267254, ISSN: 0021-9258 *
See also references of WO0138395A1 *
SIGALOV A B ET AL: "Enzymatic repair of oxidative damage to human apolipoprotein A-I", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 433, no. 3, 21 August 1998 (1998-08-21), pages 196 - 200, XP004258376, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
NZ519040A (en) 2004-02-27
CA2392355A1 (en) 2001-05-31
AUPQ429399A0 (en) 1999-12-23
JP2003514918A (en) 2003-04-22
WO2001038395A1 (en) 2001-05-31
EP1240201A1 (en) 2002-09-18

Similar Documents

Publication Publication Date Title
GB2374100B (en) Underreamer and method of use
HK1043613A1 (en) Microfibers and method of making
PL350822A1 (en) Disposable wiper-cloth and method of making same
HRP20060251B1 (en) Substituted oxasolidinones and their use
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
HK1047432A1 (en) Hemisynthetic method and new compounds
EP1223932A4 (en) Compounds and methods
EP1146790A4 (en) Compounds and methods
AU6028598A (en) Non-iron metalloporphyrins and methods of use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
EP1183030A4 (en) Methods of making and using n-desmethylzopiclone
AU4717301A (en) Catheter assembly and method of use
SG108253A1 (en) Self-adhesive tape and method of use thereof
PL350826A1 (en) Disposable wiper-cloth and method of making same
EP1240201A4 (en) Oxidized apolipoproteins and methods of use
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
GB9819898D0 (en) New vaccine and method of use
GB0022710D0 (en) Dispenser and method of use
GB2367103B (en) Connector and method of use of the connector
HUP0104723A3 (en) New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use
EP1263935A4 (en) Scytonemin and methods of using thereof
IL134210A0 (en) Use of transcription factor brn-3a
HK1041878A1 (en) Dihydropyridine compounds and methods of use
PL350963A1 (en) Use of arylalkanoylpyridazines
GB0021915D0 (en) Creating and managing E-receipts

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020626

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/775 A

Ipc: 7A 61K 38/17 B

A4 Supplementary search report drawn up and despatched

Effective date: 20040130

17Q First examination report despatched

Effective date: 20050308

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050719